Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
September 28, 2020

GSK gets FDA approval for Nucala to treat hypereosinophilic syndrome

GlaxoSmithKline (GSK) has secured approval from the US Food and Drug Administration (FDA) for its Nucala (mepolizumab) for the treatment of hypereosinophilic syndrome (HES), a rare and under-diagnosed disorder.

GSK's corporate headquarters in Brentford, London. (Credit: SmugMug+Flickr / GlaxoSmithKline plc)